{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T23:09:48Z","timestamp":1769296188400,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,24]]},"DOI":"10.7759\/cureus.102193","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T10:34:15Z","timestamp":1769250855000},"source":"Crossref","is-referenced-by-count":0,"title":["Hepatitis C Management in a Lung Cancer Patient on Checkpoint Inhibition: A Case Report"],"prefix":"10.7759","author":[{"given":"Diana","family":"P\u00f3voas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Francisca","family":"Moraes-Fontes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jos\u00e9","family":"Manata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Maltez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad344","article-title":"Direct-acting antiviral therapy for treatment of acute and recent hepatitis C virus infection: a narrative review","volume":"77","author":"Martinello M","year":"2023","unstructured":"Martinello M, Naggie S, Rockstroh JK, Matthews GV. Direct-acting antiviral therapy for treatment of acute and recent hepatitis C virus infection: a narrative review. Clin Infect Dis. 2023, 77:S238-44. 10.1093\/cid\/ciad344","journal-title":"Clin Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi L","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, et al.. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018, 378:2078-92. 10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-91102-z","article-title":"Effects of immune related adverse events and corticosteroids on the outcome of patients treated with immune checkpoint inhibitors","volume":"15","author":"\u015een GA","year":"2025","unstructured":"\u015een GA, \u00d6zta\u015f N\u015e, De\u011ferli E, et al.. Effects of immune related adverse events and corticosteroids on the outcome of patients treated with immune checkpoint inhibitors. Sci Rep. 2025, 15:6310. 10.1038\/s41598-025-91102-z","journal-title":"Sci Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Ettinger DS","year":"2022","unstructured":"Ettinger DS, Wood DE, Aisner DL, et al.. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022, 20:497-530. 10.6004\/jnccn.2022.0025","journal-title":"J Natl Compr Canc Netw"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04340-3","article-title":"Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival","volume":"149","author":"Miah A","year":"2023","unstructured":"Miah A, Tinoco G, Zhao S, et al.. Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. J Cancer Res Clin Oncol. 2023, 149:2235-42. 10.1007\/s00432-022-04340-3","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","unstructured":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025, 83.502-83. 10.1016\/j.jhep.2025.03.018","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series(\u2606)","volume":"73","year":"2020","unstructured":"EASL recommendations on treatment of hepatitis C. final update of the series(\u2606). J Hepatol. 2020, 73:1170-218. 10.1016\/j.jhep.2020.08.018","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez A","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 2021, 112:90-2. 10.1016\/j.ad.2019.05.009","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13825","article-title":"Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer","volume":"44","author":"Economides MP","year":"2016","unstructured":"Economides MP, Mahale P, Kyvernitakis A, et al.. Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer. Aliment Pharmacol Ther. 2016, 44:1235-41. 10.1111\/apt.13825","journal-title":"Aliment Pharmacol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0383-2","article-title":"Sofosbuvir-based therapy in hepatitis C virus-infected cancer patients: a prospective observational study","volume":"114","author":"Torres HA","year":"2019","unstructured":"Torres HA, Economides MP, Angelidakis G, et al.. Sofosbuvir-based therapy in hepatitis C virus-infected cancer patients: a prospective observational study. Am J Gastroenterol. 2019, 114:250-7. 10.1038\/s41395-018-0383-2","journal-title":"Am J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019013","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with HBV\/HCV infection and advanced-stage cancer: a systematic review","volume":"99","author":"Pu D","year":"2020","unstructured":"Pu D, Yin L, Zhou Y, Li W, Huang L, Cai L, Zhou Q. Safety and efficacy of immune checkpoint inhibitors in patients with HBV\/HCV infection and advanced-stage cancer: a systematic review. Medicine (Baltimore). 2020, 99:e19013. 10.1097\/MD.0000000000019013","journal-title":"Medicine (Baltimore)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002437","article-title":"High sustained virologic response rate after 8 weeks of direct-acting antivirals in cancer patients with chronic hepatitis C virus","volume":"34","author":"Yibirin M","year":"2022","unstructured":"Yibirin M, Hosry J, Yepez Guevara E, et al.. High sustained virologic response rate after 8 weeks of direct-acting antivirals in cancer patients with chronic hepatitis C virus. Eur J Gastroenterol Hepatol. 2022, 34:1098-101. 10.1097\/MEG.0000000000002437","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i45.12896","article-title":"Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma: a systematic review","volume":"21","author":"Fiorino S","year":"2015","unstructured":"Fiorino S, Bacchi-Reggiani L, de Biase D, et al.. Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma: a systematic review. World J Gastroenterol. 2015, 21:12896-953. 10.3748\/wjg.v21.i45.12896","journal-title":"World J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-020-00365-y","article-title":"Chronic hepatitis C virus infection is associated with an increased risk of lung cancer: a systematic review and meta-analysis","volume":"198","author":"Ponvilawan B","year":"2020","unstructured":"Ponvilawan B, Charoenngam N, Rujirachun P, Wattanachayakul P, Tornsatitkul S, Rittiphairoj T, Ungprasert P. Chronic hepatitis C virus infection is associated with an increased risk of lung cancer: a systematic review and meta-analysis. Lung. 2020, 198:705-14. 10.1007\/s00408-020-00365-y","journal-title":"Lung"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/v10100538","article-title":"Oncogenic signaling induced by HCV infection","volume":"10","author":"Virz\u00ec A","year":"2018","unstructured":"Virz\u00ec A, Roca Suarez AA, Baumert TF, Lupberger J. Oncogenic signaling induced by HCV infection. Viruses. 2018, 10:14-6. 10.3390\/v10100538","journal-title":"Viruses"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2013.001215","article-title":"Hepatitis C virus screening in patients with cancer receiving chemotherapy","volume":"10","author":"Hwang JP","year":"2014","unstructured":"Hwang JP, Suarez-Almazor ME, Torres HA, Palla SL, Huang DS, Fisch MJ, Lok AS. Hepatitis C virus screening in patients with cancer receiving chemotherapy. J Oncol Pract. 2014, 10:e167-74. 10.1200\/JOP.2013.001215","journal-title":"J Oncol Pract"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21403","article-title":"The oncologic burden of hepatitis C virus infection: a clinical perspective","volume":"67","author":"Torres HA","year":"2017","unstructured":"Torres HA, Shigle TL, Hammoudi N, Link JT, Samaniego F, Kaseb A, Mallet V. The oncologic burden of hepatitis C virus infection: a clinical perspective. CA Cancer J Clin. 2017, 67:411-31. 10.3322\/caac.21403","journal-title":"CA Cancer J Clin"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29344","article-title":"Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study","volume":"67","author":"Torres HA","year":"2018","unstructured":"Torres HA, Hosry J, Mahale P, Economides MP, Jiang Y, Lok AS. Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study. Hepatology. 2018, 67:36-47. 10.1002\/hep.29344","journal-title":"Hepatology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v14.i3.525","article-title":"Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: a clinical experience and a literature review","volume":"14","author":"Spera AM","year":"2022","unstructured":"Spera AM. Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: a clinical experience and a literature review. World J Hepatol. 2022, 14:525-34. 10.4254\/wjh.v14.i3.525","journal-title":"World J Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.01.271","article-title":"Hepatitis C virus infection in patients with cancer: impact on clinical trial enrollment, selection of therapy, and prognosis","volume":"157","author":"Torres HA","year":"2019","unstructured":"Torres HA, Pundhir P, Mallet V. Hepatitis C virus infection in patients with cancer: impact on clinical trial enrollment, selection of therapy, and prognosis. Gastroenterology. 2019, 157:909-16. 10.1053\/j.gastro.2019.01.271","journal-title":"Gastroenterology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/438439-hepatitis-c-management-in-a-lung-cancer-patient-on-checkpoint-inhibition-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T10:34:16Z","timestamp":1769250856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/438439-hepatitis-c-management-in-a-lung-cancer-patient-on-checkpoint-inhibition-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.102193","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,24]]}}}